CelLBxHealth plc CLBX

Buccaneer Energy Plc (AIM:BUCE, FRA:LMU1) is raising £460,000 to launch a European gas strategy, eyeing projects in Italy, Czechia and Turkey. That's alongside its Texas oil production, which generated positive cash flow in June. Predator Oil & Gas Holdings PLC (LSE:PRD) has moved its Snowcap-3 well in Trinidad closer to drilling. Site prep is underway now, with drilling and testing expected to wrap by early November. 80 Mile PLC (AIM:80M, OTCQB:BLLYF) says drilling at its Jameson Land project in Greenland is being pushed back to winter 2027. It also got a formal warning from Greenland's gover

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) jumped 6% after a new study showed its Parsortix system can spot cancer drug targets in blood samples. It even caught targets that rival tests would've missed completely. Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has dosed its first US patient with a reworked version of its cancer drug AO-252. The new capsule fixes an absorption problem and no safety issues have shown up yet. Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) got fast-tracked examination from the US patent office for its longevity gene variant. It's also had a second patent publishe

London BTC Company (LSE:BTC) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft Mine. CelLBxHealth (AIM:CLBX) says its commercially weighted pipeline has grown to £3.5 million, with second-quarter revenue doubling to £0.4 million. The company still expects at least £2.1 million in revenue for the full year. Anglo Asian Mining (LSE:AAZ) has delivered record first-half copper production of 8,840 tonnes,

ACG Metals Ltd (LSE:ACG, OTC:ACGAF) beat its full-year oxide production target in just six months, helped by a 64% jump in its realised gold price to $4,838 an ounce. First copper and zinc concentrate production is now expected in August. Rockfire Resources (LSE:ROCK) has returned more strong zinc and silver grades at its Molaoi project in Greece, with preliminary readings showing zinc values as high as 37.7%. The company is fast-tracking feasibility studies and applying for permits to reopen the underground workings. Sunda Energy (AIM:SNDA) has applied for a permit to explore an offshore area

Solvonis Therapeutics PLC (LSE, OTC) says new data supports its lead alcohol use disorder programme ahead of a planned Phase 2b trial. CEO Anthony Tennyson says the results could streamline development and open access to a market of around 15 million US adults. Tertiary Minerals PLC (AIM, OTC, FRA) has started its biggest-ever drilling programme in Zambia.  Managing director Richard Belcher says the campaign aims to define a maiden resource while testing for extensions and a potentially deeper sulphide system. CelLBxHealth PLC (AIM, FRA) is reshaping its strategy around cancer diagnostics and

Despite key collaborations and cost-saving measures, CelLBxHealth PLC (ANPCF) faces revenue declines and financial hurdles in the precision cancer diagnostics market.

Eco Buildings Group (AIM:ECOB) has completed the second floor of its first apartment block in Albania, proving its prefab building system works at scale. The block of 18 apartments should bring in around €2.2 million in revenue upon completion, with five more blocks planned. Solvonis Therapeutics (LSE:SVNS) has cleared a key hurdle for its alcohol addiction treatment, showing it delivers the same drug levels as an approved depression medicine. That clears the path towards human trials within the next two years. Coinsilium Group (AQSE:COIN) has made a strategic investment in Predictive Labs, do

CelLBxHealth (AIM:CLBX) CEO Peter Collins joined Proactive's Stephen Gunnion to discuss the company's strategic reset, progress with its Parsortix platform, and new collaborations with major healthcare and pharma players. Collins described the first half of 2026 as "an absolute whirlwind," with the company overhauling its business, product portfolio and commercial strategy — focusing on improving circulating tumour cell (CTC) recovery and viability to support both internal programmes and external partners. New board appointments bring added commercial, diagnostics, healthcare and capital marke

Last week, CelLBxHealth plc ( LON:CLBX ) insiders, who had purchased shares in the previous 12 months were rewarded...

Ariana Resources PLC (AIM:AAU, ASX:AA2, FRA:4A6) has raised US$19.5 million by selling a 13.6% stake in Turkish gold producer Zenit to fund its Dokwe gold project in Zimbabwe. The company retains a 9.9% interest in Zenit, worth an implied US$14.2 million, along with board representation and dividend rights. CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has secured a collaboration with AdventHealth, one of the largest hospital networks in the US, to deploy its cancer diagnostic platform in two clinical studies. The trials will use CelLBxHealth's technology to track how tumours respond to treatment throu

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has cut costs by more than £6.6 million and is now seeing growing demand for its circulating tumour cell diagnostic platform. CEO Peter Collins says the technology "provides information that we can't get from the tissue block," with partnerships at The Royal Marsden and a major US healthcare provider building momentum. Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) saw EBITDA jump 50% and free cash flow triple to $12 million in the first quarter, despite weaker production at its Blanket Mine in Zimbabwe. CEO Mark Learmonth says the seco

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) CEO Peter Collins tells Proactive's Stephen Gunnion that a major restructuring — cutting costs by more than £6.6 million and consolidating facilities — has repositioned the business for commercial growth just as demand for circulating tumour cell analysis accelerates. Collins is direct about the opportunity: "The need for circulating tumour cells as an important component of liquid biopsy is reiterated again and again because it provides information that we can't get from the tissue block." The company is building momentum through collaborations with The Ro

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) is in advanced talks with one of the largest private US healthcare providers to deploy its Parsortix cancer diagnostic platform. In a first quarter trading update, the company guided for revenues of at least £2.1 million this year, a 50% increase, with further upgrades possible if pipeline deals convert. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) has secured a Canadian patent for its POLB 001 drug candidate in preventing cancer immunotherapy-induced cytokine release syndrome. CEO Jeremy Skillington says the grant strengthens the drug's appeal to pa

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has teamed up with The Royal Marsden to study a blood-based testing approach in 200 advanced lung cancer patients. The trial targets patients whose standard ctDNA tests return no actionable results, with findings expected by year end. Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) has struck a collaboration with Acuitas Therapeutics, the lipid nanoparticle specialist behind several leading COVID vaccines. Acuitas will fund the work itself, which Genflow says is a strong endorsement of its SIRT6 platform. Active Energy Group PLC (AIM:AEG, OTCID:AEU